About Geron Corporation
Corporate Profile
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). We are building on our foundation in telomerase inhibition by studying imetelstat in myelofibrosis, including a pivotal Phase 3 clinical trial in patients with JAK-inhibitor relapsed/refractory disease, as well as other hematologic malignancies.
Latest Reports
responsibility
Environmental, social and governance
At Geron, we strive to make a difference for patients with blood cancer so they can enjoy a better future, while endeavoring to make a broader positive impact. We do so through efforts related to our Environmental, Social and Governance (ESG) pillars: Healthier People, Human Capital, and Governance. We look forward to all that is ahead for Geron and the treatment of patients with blood cancer.